Logo-jrip
Submitted: 18 Nov 2022
Accepted: 28 Oct 2023
ePublished: 29 Jan 2024
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

J Renal Inj Prev. 2024;13(2): e32156.
doi: 10.34172/jrip.2023.32156
  Abstract View: 235
  PDF Download: 67

Original

Astaxanthin supplementation as a potential anti-fibrotic agent in peritoneal dialysis rats

Ratih Tri Kusuma Dewi 1* ORCID logo, Bambang Purwanto 1 ORCID logo, Brian Wasita 2 ORCID logo, Vitri Widyaningsih 3 ORCID logo, Risya Cilmiaty 4 ORCID logo, Soetrisno Soetrisno 5 ORCID logo, Ratih Puspita Febrinasari 6 ORCID logo, Mahatma Chakra Wardana 1 ORCID logo, Maia Thalia Giani 1 ORCID logo, Indah Saigitaisna Putri 1 ORCID logo

1 Department of Internal Medicine, Dr. Moewardi General Hospital, Faculty of Medicine Sebelas Maret University, Surakarta, Indonesia
2 Department of Pathological Anatomy, Dr. Moewardi General Hospital, Faculty of Medicine Sebelas Maret University, Surakarta, Indonesia
3 Department of Public Health, Faculty of Medicine Sebelas Maret University, Surakarta, Indonesia
4 Department of Dentistry and Oral Health, Dr. Moewardi General Hospital, Faculty of Medicine Sebelas Maret University, Surakarta, Indonesia
5 Department of Obstetrics and Gynecology, Dr. Moewardi General Hospital, Faculty of Medicine Sebelas Maret University, Surakarta, Indonesia
6 Department of Pharmacology, Faculty of Medicine Sebelas Maret University, Surakarta, Indonesia
*Corresponding Author: Ratih Tri Kusuma Dewi, Email: ratihsolo@staff.uns.ac.id, Email: ratihsolo@gmail.com

Abstract

Introduction: Peritoneal dialysis (PD) is a recommended treatment for chronic kidney disease (CKD). Continuous exposure to dialysate solution in PD leads to peritoneal fibrosis, which is characterized by changes in morphology and function of the peritoneal membrane. Astaxanthin is considered to have potent antioxidant and anti-inflammatory properties, which has a promising anti-fibrosis effect and suppresses peritoneal thickness in peritoneal fibrosis.

Objectives: This study aimed to investigate the impact of astaxanthin supplementation on histological features among PD model rats, which determined astaxanthin as a potential anti-fibrotic agent for PD.

Materials and Methods: This study used a laboratory experimental study with a posttest-only control group design. Thirty-two male rats were divided randomly into four groups. There are two control groups and two treatment groups. Negative (NC), given intraperitoneal (IP) injection of sterilized aquadest, positive control (PC), given dialysate 4.25% injection IP. Treatment group 1 (T1) was given dialysate 4.25% injection IP and astaxanthin 0.216 mg supplementation for 14 days, and treatment group 2 (T2) was given dialysate 4.25% IP and astaxanthin 0.216 mg supplementation for 21 days. The peritoneum tissues were then collected and prepared for histological examination.

Results: Astaxanthin supplementation prevents peritoneal fibrosis development in CKD model rats (P<0.05). However, there was no significant difference in the mean fibrosis thickness based on astaxanthin duration (P>0.05).

Conclusion: Astaxanthin could reduce fibrotic thickness in PD model rats. This study was relevant to conclude that astaxanthin has a potential antifibrotic agent for PD.


Implication for health policy/practice/research/medical education:

The investigation of astaxanthin supplementation on histological peritoneal features may provide information that could improve potential adjuvant therapy to reduce fibrosis in peritoneal dialysis.

Please cite this paper as: Dewi RTK, Purwanto B, Wasita B, Widyaningsih V, Cilmiaty R, Soetrisno S, Febrinasari RP, Wardana MK, Giani MT, Putri IS. Astaxanthin supplementation as a potential anti-fibrotic agent in peritoneal dialysis rats. J Renal Inj Prev. 2024; 13(2): e32156. doi: 10.34172/jrip.2023.32156.

First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 236

Your browser does not support the canvas element.


PDF Download: 67

Your browser does not support the canvas element.